

Edgar Filing: KERSTEN GEERT R - Form 4

(Instr. 3)	Price of Derivative Security	(Month/Day/Year)	(Instr. 8)		Date Exercisable	Expiration Date	Title	Amount
			Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	Code V				
Convertible Note	\$ 2.29	07/24/2017	A	109,170	07/24/2017	12/22/2017	Common Stock	109
Series NN Warrant	\$ 2.52	07/24/2017	A	109,170	07/24/2017	07/24/2022	Common Stock	109

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
KERSTEN GEERT R		X	Chief Executive Officer	

Signatures

Geert Kersten 07/25/2017

**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

A trust in which Mr. Kersten holds a beneficial interest participated in an offering and purchased a note in the principal amount of \$250,000 as well the Series NN warrant. Shares issuable upon the conversion of the notes or exercise of the warrant will be restricted securities unless registered. The number of securities beneficially owned gives effect to the 25-for-1 reverse stock split which became effective on June 15, 2017, and include Series N warrants (as amended) to purchase 85,339 shares of common stock held by the de Clara Trust. The amended Series N warrants expire on August 18, 2018 and are exercisable at a price of \$3.00 per share.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.